Chloroquine News and Research

RSS

Pharmacophore model helps find key protease inhibitor responsible for COVID-19

A team of San Diego Supercomputer Center (SDSC) researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19.

2 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Chloroquine/hydroxychloroquine could treat COVID-19 infection

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths, and a large number of open cases.

1 Dec 2020

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

3D8, a 27-kDa recombinant antibody fragment, was found in autoimmune-prone Murphy Roths Large mice. The single-chain variable fragment (scFv) has the nucleic acid hydrolyzing activity and is shown to degrade DNA or mRNA of viruses in infected cells.

30 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

Care pathways for pregnant women with COVID‐19

A recent review published in the journal Global Challenges in October 2020, sums up what is currently known about the treatment of COVID-19 during pregnancy and offers recommendations for how healthcare professions might better manage pregnant COVID-19 patients in the future.

16 Nov 2020

Patients with rheumatic diseases reported antimalarial drug shortages during COVID-19

A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs, including hydroxychloroquine, during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment.

6 Nov 2020

Genome-wide CRISPR screens reveal resistance and sensitization mechanisms of drugs used in COVID-19

By leveraging nucleotide triphosphate analog-induced cell death, Chinese researchers unveiled genes that affect the import, export, and metabolism of pervasively used antiviral drugs in the treatment of coronavirus disease (COVID-19). This exciting study is currently available on the bioRxiv* preprint server.

28 Oct 2020

Research on autophagy and coronavirus, implicates ULK1

Researchers from the University of British Columbia have discovered that the betacoronavirus-encoded papain-like protease disrupts autophagy, partly by targeting ULK1. Their work is reported on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

Can ordinary COVID patients get the Trump treatment? It’s OK to ask

When Terry Mutter woke up with a headache and sore muscles on a recent Wednesday, the competitive weightlifter chalked it up to a hard workout.

20 Oct 2020

Exploring the effects of smoking tobacco on COVID-19 risk

A study conducted by researchers in China has shed light on how certain tobacco compounds might prevent cells from becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

14 Oct 2020

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Study compares the effect of hydroxychloroquine versus favipiravir in SARS-CoV-2−infected hamsters

Virologists at the Rega Institute have shown that the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters.

9 Oct 2020

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.

6 Oct 2020

A special issue on the emerging COVID-19 infection

Acta Pharmaceutica Sinica B publishes special issue on 'Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)' edited by Hai-Bin Luo, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Materia Medica, Beijing, China and Peiqing Liu, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

29 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Cardiovascular adverse events linked to hydroxychloroquine and chloroquine

As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, it's now more important than ever to have a thorough assessment of the safety of these medications.

23 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of COVID-19 have revolved around the drug's reputation for causing cardiac events such as abnormal heart rhythms or beats and cardiac arrest.

16 Sep 2020